A
20.71
-0.62 (-2.91%)
| 前收盘价格 | 21.33 |
| 收盘价格 | 21.42 |
| 成交量 | 1,706,483 |
| 平均成交量 (3个月) | 1,993,957 |
| 市值 | 2,863,323,136 |
| 预期市盈率 (P/E Forward) | 111.11 |
| 价格/销量 (P/S) | 7.92 |
| 股市价格/股市净资产 (P/B) | 9.16 |
| 52周波幅 | |
| 利润日期 | 7 Aug 2025 |
| 营业毛利率 | -26.41% |
| 营业利益率 (TTM) | 70.24% |
| 稀释每股收益 (EPS TTM) | -1.24 |
| 季度收入增长率 (YOY) | -29.60% |
| 总债务/股东权益 (D/E MRQ) | 108.23% |
| 流动比率 (MRQ) | 5.15 |
| 营业现金流 (OCF TTM) | 61.15 M |
| 杠杆自由现金流 (LFCF TTM) | -6.46 M |
| 资产报酬率 (ROA TTM) | -5.86% |
| 股东权益报酬率 (ROE TTM) | -26.22% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Arrowhead Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.6
| 分析师共识 | 5.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.60 |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 13.02% |
| 机构持股比例 | 77.19% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 80.00 (HC Wainwright & Co., 286.29%) | 购买 |
| 中 | 60.00 (189.72%) | |
| 低 | 38.00 (RBC Capital, 83.49%) | 购买 |
| 平均值 | 59.33 (186.48%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 23.52 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Oct 2025 | 80.00 (286.29%) | 购买 | 36.94 |
| 02 Sep 2025 | 80.00 (286.29%) | 购买 | 25.68 | |
| Chardan Capital | 11 Aug 2025 | 60.00 (189.72%) | 购买 | 17.21 |
| RBC Capital | 08 Aug 2025 | 38.00 (83.49%) | 购买 | 16.42 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合